Kinnov Therapeutics

Alcohol use disorder
#Alcohol Use Disorder #Kinnov Therapeutics #Neuroscience #Phase II trial

Drug halves alcohol consumption to aid alcohol dependence

Kinnov Therapeutics’ Phase II study for its lead compound KT-110 has shown that the treatment can halve alcohol consumption amongst heavy drinkers in three months. The trial showed that KT-110 has superior efficacy in significantly reducing alcohol consumption in heavy drinkers by 26 to 30 grams… Read More

#News